VACCINA VIRUS VECTORED HIV VACCINES

疫苗病毒载体 HIV 疫苗

• 批准号: 3810429
• 负责人: THOMAS R FUERST
• 金额: --
• 依托单位: MEDIMMUNE, INC.
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3810429
• 关键词: B lymphocyte; antibody neutralization test; antiviral antibody; cytotoxic T lymphocyte; genetic manipulation; helper T lymphocyte; human immunodeficiency virus; humoral immunity; immunomodulators; laboratory mouse; synthetic peptide; transposon /insertion element; vaccinia virus; viral vaccines; virus antigen

Vaccinia virus has proven safe and effective in eradicating smallpox, and has considerable promise as an expression vector for vaccine development. Its ability to accommodate more than 25 kilobases of exogenous DNA without impairing its ability to replicate, and, to present antigen(s) either intracellularly or on the surface of infected cells, as required, has been used successfully to identify or condirm the targets of and to stimulate specifically both cell-mediated and humoral immune responses. We plan to use vaccinia virus vectors to identify important HIV epitopes for vacccine development. Using novel techniques and promoters previously developed in our laboratories, we will construct novel vaccinia virus recombinant to express recombinant genes encoding multiple repeats of potent B cell and Th and Tc epitopes from single and multiple isolates of HIV. These recombinant vaccinia viruses will be assessed in a mouse model system for their ability to induce broadly reactive neutralizing antibody and CMI responses against multiple HIV variants. This approach should lead to the construction of novel, live recombinant vaccine candidates capable of providing protection against HIV infection.

Vaccinia病毒已被证明是安全有效地消除的 天花，作为表达向量有很大的希望 疫苗开发。 它容纳25多个能力 外源性DNA的千倍酶，而不会损害其能力 复制，并在细胞内或呈现抗原 根据需要使用感染细胞的表面 成功地识别或生产并刺激目标并刺激目标 特别是细胞介导的和体液免疫反应。 我们 计划使用离甲酸病毒媒介来识别重要的艾滋病毒 发电机开发的表位。 使用新颖的技术和 以前在我们的实验室中开发的发起人，我们将 构建新型的离与病毒重组以表达重组 编码有效B细胞和Th和TC多次重复的基因 来自HIV的单个和多个分离株的表位。 这些 重组疫苗病毒将在小鼠模型中进行评估 系统的系统能够诱导广泛反应性中和 针对多种HIV变异的抗体和CMI反应。 这 方法应导致小说，现场重组的构建 候选疫苗能够提供抗艾滋病毒的疫苗 感染。